9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingAs we continue our journey toward advancing awareness and understanding of celiac disease, it is crucial that we reflect on health equity and the persistent clinical disparities within our community—so that together we can confront these factors and dismantle barriers hindering access to care and support. Health equity represents the...